Abstract: A cosmetic composition for the cosmetic treatment of keratin fibers is provided. The composition includes: (a) fibers, (b) ethanol, (c) at least one polymer, and (d) propellant.

Abstract: This present invention provides dissolvable solid articles comprising multiple layers of flexible, dissolvable, porous sheets, in which a coating composition is present on at least one internal surface of at least one sheet in said solid articles. The present invention also provides a process for making such solid articles.

Abstract: The present invention relates to a device for dispensing a product for dyeing keratin fibers, comprising a dye composition (A) having one or more oxidation dyes and one or more alkaline agents as well as an oxidizing composition (B) having one or more chemical oxidizing agents, either of the compositions (A) and/or (B) comprising one or more scleroglucan gums preferably in a total weight content greater than or equal to 0.5% relative to the total weight of the composition(s) (A) and/or (B) containing them. The invention also relates to a method for dyeing keratin fibers using said device.

Abstract: The present invention relates to a composition, in particular cosmetic, in the form of an oil-in-water emulsion, comprising a continuous aqueous phase and a dispersed oil phase in the form of drops (G1) and drops (G2), wherein the size of the drops (G1) is less than 500 ?m and the size of the drops (G2) is greater than 500 ?m.

Abstract: The present invention relates to capsules comprising a peptide, lecithin, alginate, and divalent metal cation, compositions comprising said capsules, use thereof in cosmetic treatments, as well as methods of obtaining said capsules.

Abstract: The invention relates to compositions for removing nail polish comprising at least at least about 10% by weight of at least one polyhydric alcohol compound, at least one low carbon alcohol, at least one high boiling point ester compound, at least one thickening agent, and at least one abrasive compound, as well as to methods of removing nail polish from nails using such compositions.

Abstract: The present invention is direct to a hair care composition comprising from about 8 to about 17% of one or more surfactants; from about 0.1-0.25% of salicylate salts or acids; from about 0.1-0.25% of benzoate salts or acids wherein there is a weight ratio of about 1:1 to 2.5:1 for the salicylate salts or acids to sodium benzoate salts or acids.

Abstract: The invention relates to a composition in the form of a nanoemulsion or microemulsion, comprising: at least two different fatty acid esters of (poly)glycerol a) and b); c) at least one polyol in a total content of greater than 15% by weight; d) at least one oil; e) water; and f) at least one anionic surfactant of formula (II) it being understood that said composition comprises at least one anionic surfactant of formula (II) when the first fatty acid ester of (poly)glycerol is a polyglyceryl laurate comprising from 3 to 6 glycerol units and the second fatty acid ester of (poly)glycerol is a (poly)glyceryl laurate comprising from 1 to 3 glycerol units. The invention also relates to a cosmetic treatment process for reducing and/or preventing the signs of ageing of keratin materials such as the skin, by application of such a composition.

Abstract: The invention relates to a composition for use in a method of treating caries by reducing the lactic acid release of lactic acid producing bacteria in an oral biofilm of a human being or animal, the composition comprising one or more amino acid(s) dissolved or dispersed in water, the amino acid(s) being selected from glycine, leucine, isoleucine, lysine, methionine, phenylalanine, serine, threonine, valine, tryptophan and mixtures thereof. The invention also relates to a kit of parts for use in a method of treating caries by reducing the caries activity or reducing the lactic acid release of lactic acid producing bacteria in an oral biofilm, the kit of parts comprising Part A comprising certain amino acid(s), Part B comprising water, and optionally Part C comprising an application device.

Abstract: The present invention is directed to a hair care composition comprising from about 8 to about 17% of one or more surfactants and from about 0.04 to about 0.18% of salicylate salts or acids.

Abstract: The present invention is directed to hair care composition comprising from about 8 to about 17% of one or more surfactants; from about 0.01% to about 10% of one or more surfactant soluble antidandruff agents; from about 0.01% to about 5% of one or more polyacrylate or polyacrylamide based thickening polymer; from about 0.02-0.25% salicylate salts or acids; from about 0.02-0.25% benzoate salts or acids wherein there is a weight ratio of about 1:1 to 12.5:1 for the salicylate salts or acids to benzoate salts or acids.

Abstract: A problem of the present invention is to provide a novel composition for anti-aging. The means for solving the problem is to use one or multiple compounds such as a lophenol compound, and a cyclolanostane compound as active ingredients of the composition for anti-aging.

Abstract: The present invention relates to a method for the protection of human skin against visible light damages, namely blue light, said method comprising the step of applying a cosmetic composition containing an effective amount of vitamin B3 or a derivative thereof and an effective amount of vitamin B6 or derivative thereof to the skin.

Abstract: The disclosure relates to a composition for dyeing keratin fibers, in particular human keratin fibers such as hair, comprising one or more oxidation dyes, one or more scleroglucan gums in a total weight content greater than or equal to 0.5% relative to the total weight of the composition, and one or more associative polymers comprising at least one fatty chain having 8 to 30 carbon atoms, preferably non-ionic. The disclosure also relates to a method for dyeing keratin fibers using said composition and to a multi-compartment device suitable for implementing said composition.

Abstract: A composition for improved oral care includes fibrillated material and friction elements for removal of plaque biofilm, and additional ingredients useful in oral care compositions. The composition also may include particulate SuperAbsorbent Polymer, which may be surface cross-linked. Certain ingredients may be minimized or avoided to reduce the lubricity of the composition. The composition may be a viscoelastic fluid having a desired viscosity, yield stress and elastic modulus. The efficacy can be characterized by its removal of biofilm due to flow inside tubes. Also useful are standard rheological and tribological measurements. Also disclosed are apparatus for administering the composition, and methods.

Abstract: A hair styling composition comprising at least one cationically modified polygalactomannan having a molecular weight in a range of from about 40 to about 1100 KDa and at least one cosmetic ingredient is disclosed. Also disclosed is a method of use thereof and a process for preparing the same.

Abstract: Personal care products are provided. An exemplary personal care product includes a composition that is applied to the body or clothing, or an article applied against the body; a plurality of particles associated with the composition or a component of the article, the plurality of particles, at least some of the plurality of particles comprising a cyclodextrin complexing material and a first fragrance material, wherein the percent of the first fragrance material that is complexed with the cyclodextrin is greater than about 90%, so that the perceptibility of the first fragrance is minimized prior to its release; and a second fragrance material that is not complexed with the cyclodextrin and that is different from the first fragrance material, wherein the composition or article does not contain an antiperspirant active.

Abstract: A product for cosmetic skin care includes, comprising an applicator and an active-care cosmetic composition. The applicator is constituted by an ergonomic metallic body adapted for skin contact, in which a permanent magnet with magnetic field strength substantially comprised of an amount between 0.1 mT and 10 mT is at least partially embedded.

Abstract: The present invention relates to a composition, especially comprising a physiologically acceptable medium, especially for coating keratin materials, more particularly for making up and/or caring for keratin materials such as the skin, and containing a) at least one ester-terminated poly(ester-amide) polymer; and b) at least one volatile alkane; and c) at least one tackifying resin chosen from the group constituted of indene hydrocarbon-based resins, pentadiene aliphatic resins, cyclopentadiene aliphatic resins, mixed resins of pentadiene and of indene, cyclopentadiene dimer diene resins, isoprene dimer diene resins, hydrogenated resins resulting from the polymerization of pentadiene, hydrogenated resins resulting from the polymerization of cyclopentadiene, and mixtures thereof. and d) a particulate phase comprising at least one pigment.

Abstract: The present invention provides a composition for use in the treatment of the air pollution effects on the skin or for the premature skin aging associated with the air pollution effects. The composition includes diterpenes, oleuropein, verbascoside, quercetin and hydroxytyrosol. In a preferred embodiment, the composition contains around 32% by weight of rosemary extract with a minimum diterpene content of 15% by weight, around 30% by weight of an olive fruits or leaves extract with a minimum oleuropein content of 16% by weight and a minimum hydroxytyrosol content of 5% by weight, around 28% by weight of a Lippia citriodora extract with a minimum verbascoside content of 25% by weight and around 10% by weight of a Sophora japonica extract with a minimum quercetin content of 40% by weight.

Abstract: Oral care compositions with an anticaries or anticavity effect. Oral care compositions that have one or more hops beta acids, such as from an extract from a species in the Humulus family, and one or more amino acids. Oral care compositions having one or more amino acids and an extract from Humulus lupulus. Methods of us of the disclosed compositions to disrupt biofilm in the oral cavity of a patient in need of treatment.

Abstract: A cosmetic composition containing rose stem cell-derived exosomes as an active ingredient is provided for skin regeneration, skin elasticity improvement or skin wrinkle reduction. The cosmetic composition has excellent effects on skin regeneration, skin elasticity improvement and/or skin wrinkle reduction.

Abstract: The present disclosure discloses a skin penetration enhancing composition and a use thereof in preparation of a skin delivery formulation. The skin penetration enhancing composition comprises sponge spicules and nanoparticles. The nanoparticles comprise at least one of one or more drugs or one or more cosmetic active ingredients.

Abstract: Pre-filled syringes, pharmaceutical compositions, and kits and methods relating to same allow for emergency administration of one or more drugs from prefilled glass syringes to a patient via a needleless connector. In preferred embodiments, the prefilled glass syringe has a drug volume of at least 5 mL, has a Luer-lock, and has a syringe tip with an internal channel that has a diameter of about 1.7 mm. Such syringes advantageously allow storage of emergency drugs without leaching of plastic materials and degradation, and substantially improve the safety profile where the syringe is attached to an IV line via a needleless connector.

Abstract: A personal lubricant disk is described. The personal lubricant disk typically comprises a composition that is solid at ambient room temperature and melts into a liquid when placed and moved around the bodily surface of a human person. Variations of the personal lubricant disk composition can also include ingredients the stimulate different sensory reactions when the personal lubricant disk is placed and moved around the bodily surface, such as a warming or cooling sensation, as well as various pleasant tastes or scents.

Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

Abstract: The present invention relates to gastroretentive formulations and to processes for preparation of the same. Particularly, the invention relates to gastroretentive dosage forms comprising at least one swelling agent and at least one swelling retardant.

Abstract: The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.

Abstract: A sugar-responsive gel that is highly resistant to temperature changes, and a sugar-responsive drug delivery device including such a gel. The sugar-responsive gel, which comprises a gel composition including a monomer having a hydroxyl group in addition to a phenylboronic-acid-based monomer, can exhibit suitable temperature resistance. A sugar-responsive drug delivery device including such a sugar-responsive gel is less susceptible to the effects of temperature changes, and therefore can prevent undesirable excessive delivery of a drug such as insulin.

Abstract: The present disclosure provides lipid emulsions comprising at least 20 percent (w/v) lipid with an average particle size of about 200 to about 300 nm, and use thereof to treat subjects in need of lipid emulsion therapy.

Abstract: The invention provides a compartmentalised gel matrix comprising one or more compartments, wherein each compartment comprises a volume of hydrophobic medium and one or more aqueous droplets therein. The invention further provides a pharmaceutical formulation comprising a compartmentalised gel matrix according to the invention, a synthetic cell comprising a compartmentalised gel matrix according to the invention and a synthetic tissue comprising a compartmentalised gel matrix according to the invention.

Abstract: Methods of preparing free-flowing powder from cannabinoid oils, including, but not limited to broad or full spectrum cannabidiol (CBD) oil, generally include granulating a cannabinoid oil with a granulating agent to form a granulated mixture, mixing a binder and/or filler with the granulated mixture to adjust the size of the granules in the granulated mixture, and mixing flow agent with the granulated mixture. The methods described herein can also include mixing bioavailability enhancer with the granulated mixture to improve the bioavailability of the cannabinoid compound in the free-flowing powder.

Abstract: An oral cannabis composition comprising molecularly separated cannabinoids, MCT oil and a terpene blend. A method of producing the oral cannabis composition comprising the steps of a) producing cannabis extract by supercritical carbon dioxide extraction; b) after step a), winterizing the cannabis extract; c) after step b), distilling the winterized cannabis extract to produce molecularly separated cannabinoids; d) after step c), mixing the molecularly separated cannabinoids with MCT oil; and e) after step d), mixing the mixture of MCT oil and molecularly separated cannabinoids with a terpene blend. A second method comprises the steps of a) selecting a desired mixture of molecularly separate cannabinoids; b) after step a), mixing the molecularly separated cannabinoids with MCT oil; and c) after step b), mixing the mixture of MCT oil and molecularly separated cannabinoids with a terpene blend.

Abstract: A method for formulating an active pharmaceutical ingredient (API) comprises mixing the API and micronized polymer matrix particles comprising polymer strands and having a mean geometric particle diameter in a range of from about 0.1 to about 100 microns, wherein the API is in a liquid phase, to form a homogeneous slurry, allowing the polymer matrix particles to absorb the API, and drying the slurry to form a composite material. The composite material facilitates formation of a tablet or other solid unit dosage form containing the API and/or improves dissolution of the API, for example, in vivo.

Abstract: The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.

Abstract: The present disclosure relates to a dry process for preparing a solid pharmaceutical dosage form of vitamin K1 comprising: a) blending vitamin K1 with a first diluent under a first set of pre-determined conditions to obtain a first mixture; b) contacting the first mixture with a second diluent under a second set of pre-determined conditions to obtain a second mixture; c) mixing the second mixture with the excipients selected from a group consisting of disintegrant, lubricant and glidant under a third set of pre-determined conditions to obtain a third mixture; and d) compressing or encapsulating the third mixture to obtain the solid pharmaceutical dosage form of vitamin K1.

Abstract: Improved treatments of inflammation caused by HIV using cannabinoids. An exemplary treatment according to the present invention includes administration of an oral solution having a THC+CBD formulation in a 1:1 ratio.

Abstract: The objective of the present invention is to provide a capsule filling composition which can stably produce a capsule formulation by suppressing the flow of components out of the capsule body during capsule filling, regardless of the compressibility of an active ingredient such as drugs and health foods, so that a favorable capsule filling can be achieved; and a method of producing a capsule formulation with the use of such a capsule filling composition, as well as a capsule formulation. The objective is achieved by a method of producing a capsule formulation, comprising subjecting a capsule filling composition containing an active ingredient and a cellulose ether powder to a funnel system powder filling or a die-compression system powder filling to obtain the capsule formulation, and the like.

Abstract: The present invention relates to a method for improving lactic acid bacteria in survival rate, storage stability, resistance to acid or bile, and adherence to intestinal epithelial cells by coating the surface of lactic acid bacteria with silk fibroin, and a lactic acid bacteria composition prepared therethrough. Conventional techniques construct only a physical protective barrier outside a lactic acid bacteria body by multi-stage coating and thus retain the limitation of being unable to identify an effect on the coherence of lactic acid bacteria to intestinal epithelial cells upon the uptake of the lactic acid bacteria. In contrast, the present invention provides a method in which lactic acid bacteria is coated with silk fibroin extracted from cocoons, whereby the lactic acid bacteria is improved in stability under a storage and distribution condition as well as having remarkably increased stability and intestinal adherence particularly under an intestinal environment.

Abstract: In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. These compositions may include a cationic ionizable lipid, a phospholipid, a PEGylated lipid, and a steroid including using less of a cationic ionizable lipid than compositions with shorter nucleic acids. These compositions may be used to treat a disease or disorder for which the delivery of an mRNA is therapeutically effective.

Abstract: Systems and methods for targeting specific cancer cell subpopulations present in tumor tissue are described. A system can include a first component for specifically targeting cancer stem cells and a second component for specifically targeting differentiated cancer cells. A system can include a drug conjugated to small (e.g., 5-20 nm) nanoparticles, e.g., polyhedral oligomeric silsesquioxane nanoparticles. The small nanoparticles can be preferentially taken up by cancer stem cells via macropinocytosis and can release a toxic payload within the cancer stem cells without triggering the efflux pump. A system can include a second component that targets differentiated cancer cells, e.g., a free drug or a drug encapsulated in nanoparticles.

Abstract: Provided herein are immunomodulatory nanoparticles, compositions containing the same, and methods of use thereof, such as for the treatment of traumatic brain injury.

Abstract: The object of the present invention is the method for obtaining a pharmaceutical composition of polymeric nanoparticles for the treatment of neuropathic pain caused by peripheral nerve compression, related to the pharmaceutical industry and nanotechnology. The invention particularly relates to a novel system for orally administering the cannabinoid drug CB13 based on polymeric nanoparticles capable of alleviating pain for nine days following a single oral administration of an aqueous suspension of nanoparticles.

Abstract: A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.

Abstract: At least one protein-bound cannabinoid bound to a plasma protein for use as a medicament for treatment of a condition, wherein a total cannabinoid dose of the at least one protein-bound cannabinoid, administered over a time period comprising multiple administrations, is lower relative to a total cannabinoid dose of the at least one cannabinoid when administered in unbound form for achieving a same degree of therapeutic effect for treating the condition.

Abstract: An object of the present invention is to provide a composition that can be used as a novel anti-inflammatory agent. An inflammation such as stomatitis, oral mucositis, gingivitis, or pneumonia can be ameliorated and/or prevented by using a composition comprising olanexidine or a pharmacologically acceptable salt thereof. The composition of the present invention preferably further comprises a poloxamer which is a block copolymer consisting of a chain of polyoxypropylene (POP) and two chains of polyoxyethylene (POE) flanking the POP.

Abstract: Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating kidney disease, such as nephrotic syndromes.

Abstract: The present disclosure is related to a metformin compounded composition and application thereof. The disclosure provides active ingredients of composition dosage forms, comprising active ingredients including metformin, omega-3 fatty acid, statin, and vitamins. The whole or part of the active ingredients can be manufactured into a single dosage form for preventing or treating a special disease or enhance health in general. The diseases that can be prevented or treated include cardiovascular diseases, nervous system diseases, cancer, diabetes, autoimmune diseases, or any other diseases that can be treated with the provided formulations. Because of the broad applicability for preventing diseases and enhancing health, the application of the invented formulation may provide “health and longevity” for general population.

Abstract: The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.

Abstract: A pharmaceutical composition comprising lidocaine N-oxide (LNO), or a pharmaceutically acceptable salt thereof, for use in a method of treatment, said method being a prophylactic treatment to prevent, or decrease the likelihood of, sudden cardiac death associated with ventricular fibrillation (VF) in a subject, whereby the composition is provided to the subject's bloodstream via the oral mucous membrane or via pulmonary absorption in the lungs or by IV administration.